BD Solutions for Efficient Management of HAIs

Healthcare-associated infections (HAIs) are a major cause of morbidity and mortality around the world. An estimated 6 million healthcare-associated infections occur each year across the U.S., Europe and Japan alone. Beyond the human toll, HAIs poses an enormous financial burden to healthcare systems worldwide. BD is committed to applying its expertise, resources and technologies toward the prevention of healthcare-associated infections worldwide. Helping to prevent HAIs perfectly aligns with BD's core purpose of "helping all people live healthy lives".

BD Diagnostics offers you a comprehensive range of assays (Screening/Diagnostic; Molecular/ Chromogenic/ Conventional) to identify HAI causing organisms in the most efficient way corresponding to your unique and individual setting.

For the latest information on BD's strategy concerning HAIs, please sign up at BD HAIs Web site

Learn more about...

[bullet] New Assay Rapidly Identifies Lethal Pathogen Responsible for Clostridium difficile Infection »

[bullet] First Healthcare-Associated Infection Assay on the BD MAX™ System Launches in Europe »

[bullet] BD Diagnostics and Biodiversity Collaborate to Develop Portfolio of Assays on the BD MAX™ System »

[bullet] BD and Lab21 Collaborate to Develop Aspergillus Assay for New BD MAX™ Molecular Testing System »

[bullet] BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians »

[bullet] BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System »

[bullet] Literature References »

[bullet] BD Completes Acquisition of HandyLab, Inc. »

[bullet] BD Adds Surveillance Capability to Infectious Disease Portfolio » »

[bullet] BD GeneOhm™ Cdiff Assay CE Marked and Submitted for FDA Clearance »

HAI Archive»